MedPath

Hta Co., Ltd.

Hta Co., Ltd. logo
🇨🇳China
Ownership
Public, Subsidiary
Established
2001-05-18
Employees
-
Market Cap
-
Website
https://www.atom-hitech.com

Clinical Trials

6

Active:1
Completed:2

Trial Phases

3 Phases

Phase 1:1
Phase 3:3
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 3
3 (50.0%)
Not Applicable
2 (33.3%)
Phase 1
1 (16.7%)

Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs

Not Applicable
Active, not recruiting
Conditions
NETs
Interventions
Drug: 68Ga-DOTATATE Injection
First Posted Date
2025-08-13
Last Posted Date
2025-08-13
Lead Sponsor
HTA Co., Ltd.
Target Recruit Count
95
Registration Number
NCT07119242
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

Not Applicable
Recruiting
Conditions
NETS Ga68 Lu177
Interventions
Drug: 177Lu-DOTATATE injection
First Posted Date
2025-07-10
Last Posted Date
2025-07-10
Lead Sponsor
HTA Co., Ltd.
Target Recruit Count
184
Registration Number
NCT07057622
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Phase 3
Recruiting
Conditions
Prostate Cancer
Interventions
Drug: Florastamin[18F] Injection
First Posted Date
2024-12-31
Last Posted Date
2024-12-31
Lead Sponsor
HTA Co., Ltd.
Target Recruit Count
131
Registration Number
NCT06754085
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, China

A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection

Phase 1
Completed
Conditions
MCI
AD
Interventions
First Posted Date
2024-09-19
Last Posted Date
2025-07-10
Lead Sponsor
HTA Co., Ltd.
Target Recruit Count
28
Registration Number
NCT06593626
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer

Phase 3
Recruiting
Conditions
Prostate Cancer
Interventions
First Posted Date
2023-08-25
Last Posted Date
2023-10-23
Lead Sponsor
HTA Co., Ltd.
Target Recruit Count
267
Registration Number
NCT06011304
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, China

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.